drugset / Trial / NCT03629015
Safety Study of Stemchymal® in Acute Liver Failure
NaSequentialOpen-labelTreatment
Summary
To investigate the safety of Stemchymal® via intravenous (IV) infusion in acute liver failure (ALF) and acute on chronic liver failure (ACLF) patients.
Timeline
- Start
- 2018-10-01
- Primary completion
- 2020-05-18
- Completion
- 2020-05-18
Outcome
Outcome not reported
Stopped (Business): “Corporate strategic consideration”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Stemchymal® | Cell therapy | 0.5 cells/kg | Intravenous |
| Subject | Stemchymal® | Cell therapy | 2 cells/kg | Intravenous |